What 	What 	 WP	O
's  	's  	 VBZ	O
new  	new  	 JJ	O
in  	in  	 IN	O
dermatological  	dermatological  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
?  	?  	 .	O
Several  	Several  	 JJ	O
good-quality  	good-quality  	 JJ	B-NP
randomised  	randomised  	 JJ	I-NP
trials  	trials  	 NNS	I-NP
brought  	brought  	 VBD	O
useful  	useful  	 JJ	O
information  	information  	 NN	O
on  	on  	 IN	O
how  	how  	 WRB	O
to  	to  	 TO	O
manage  	manage  	 VB	O
severe  	severe  	 JJ	O
skin  	skin  	 NN	O
infections  	infections  	 NNS	O
and  	and  	 CC	O
develop  	develop  	 VB	O
anti-staphylococcus  	anti-staphylococcus  	 JJ	B-NP
strategies 	strategies 	 NNS	I-NP
.  	.  	 .	O
Trials  	Trials  	 NNS	O
on  	on  	 IN	O
common  	common  	 JJ	O
warts  	warts  	 NNS	O
did  	did  	 VBD	O
not  	not  	 RB	O
bring  	bring  	 VB	O
any  	any  	 DT	O
valuable  	valuable  	 JJ	O
solution 	solution 	 NN	B-NP
.  	.  	 .	O
Rituximab  	Rituximab  	 NNP	B-NP
and  	and  	 CC	O
omalizumab  	omalizumab  	 NNS	B-NP
have  	have  	 VBP	O
seen  	seen  	 VBN	O
their  	their  	 PRP$	O
indications  	indications  	 NNS	O
becoming  	becoming  	 VBG	O
more  	more  	 RBR	O
precise  	precise  	 JJ	O
or  	or  	 CC	O
broadened 	broadened 	 VBD	O
.  	.  	 .	O
Meta-analyses  	Meta-analyses  	 NNS	B-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
particularly  	particularly  	 RB	O
numerous 	numerous 	 JJ	O
,  	,  	 ,	O
but  	but  	 CC	O
most  	most  	 JJS	O
of  	of  	 IN	O
the  	the  	 DT	O
time  	time  	 NN	O
with  	with  	 IN	O
no  	no  	 DT	O
decisive  	decisive  	 JJ	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
since  	since  	 IN	O
this  	this  	 DT	O
methodology  	methodology  	 NN	O
presents  	presents  	 VBZ	O
strong  	strong  	 JJ	O
limitations  	limitations  	 NNS	O
for  	for  	 IN	O
studying  	studying  	 VBG	B-NP
safety  	safety  	 NN	I-NP
data 	data 	 NNS	I-NP
.  	.  	 .	O
Most  	Most  	 RBS	O
important  	important  	 JJ	O
work  	work  	 NN	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
rather  	rather  	 RB	O
directed  	directed  	 VBN	O
toward  	toward  	 IN	O
analysing  	analysing  	 JJ	O
safety  	safety  	 NN	O
data  	data  	 NNS	O
rather  	rather  	 RB	O
than  	than  	 IN	O
efficacy 	efficacy 	 NN	O
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
important  	important  	 JJ	O
results 	results 	 NNS	O
,  	,  	 ,	O
are  	are  	 VBP	O
those  	those  	 DT	O
from  	from  	 IN	O
a  	a  	 DT	O
retrospective  	retrospective  	 JJ	B-NP
cohort  	cohort  	 NN	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
taking  	taking  	 VBG	O
isotretinoin 	isotretinoin 	 NNS	B-NP
:  	:  	 :	O
suicidal  	suicidal  	 JJ	B-NP
risk  	risk  	 NN	I-NP
has  	has  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
linked  	linked  	 VBN	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
acne  	acne  	 NN	O
itself 	itself 	 PRP	O
,  	,  	 ,	O
rather  	rather  	 RB	O
than  	than  	 IN	O
to  	to  	 TO	O
the  	the  	 DT	O
drug 	drug 	 NN	O
.  	.  	 .	O
